Regen BioPharma Inc (RGBP)

[Schuller]

I spoke with Harry Lander shortly after the Kite deal was announced and he said Regen had the identical science but about a year behind and needed 25M to get to that point. Regen has since shelved that science in favour of the two mRNA IND's they have submitted which indicates how valuable they believe they are.

So I thought the company needed to get into first phase clinical with some positive results to attract buyers. This new patent on taking carT cell back to their strongest point could be a "game changer" and I'm not using those words loosely, but this is.

This alone could attract a lot of attention that I'm not even sure clinical trials will be necessary. Regen's associations with Cornell may be a very fortunate break for them and in essence investors.
For the first time since buying stock in this company I do believe that we could actually wake up one morning to a sale.

Good Luck!!!